Rush University, Chicago, Illinois.
Rush University, Chicago, Illinois.
Ann Allergy Asthma Immunol. 2019 Sep;123(3):232-239. doi: 10.1016/j.anai.2019.07.004. Epub 2019 Jul 8.
To identify the need for cost-effectiveness analysis of biologic therapies in the treatment of chronic rhinosinusitis (CRS).
Clinical trials of monoclonal antibodies (omalizumab, benralizumab, mepolizumab and dupilumab) for nasal polyposis or chronic rhinosinusitis published on PubMed.
Clinical trials of biologic therapies in CRS and nasal polyposis.
No cost-effectiveness analyses of biologic therapies in CRS have been performed.
As more clinical trials of biologic therapies for CRS are conducted, there is a need for cost-effectiveness analysis. Future analyses should consider these therapies as part of medical therapeutic options compared with surgery. To increase generalizability, analyses should include samples from allergy and primary care clinics rather than only otolaryngology clinics.
确定生物疗法治疗慢性鼻-鼻窦炎（CRS）的成本效益分析的必要性。
在 PubMed 上发表的针对鼻息肉或慢性鼻-鼻窦炎的单克隆抗体（奥马珠单抗、贝那鲁肽、美泊利单抗和度普利尤单抗）的临床试验。
CRS 和鼻息肉的生物疗法临床试验。
尚未对 CRS 的生物疗法进行成本效益分析。
随着更多针对 CRS 的生物疗法临床试验的开展，需要进行成本效益分析。未来的分析应将这些疗法作为与手术相比的医疗治疗选择的一部分来考虑。为了提高普遍性，分析应包括来自过敏和初级保健诊所的样本，而不仅仅是耳鼻喉科诊所的样本。
